BIOSCIENCE

BIOSCIENCE

NCT01443104

Orsiro Sirolimus-eluting stent with biodegradable polymer vs Xience Prima everolimus-eluting stent

Conclusion

  • In this 2,119 patient, randomized, all-comers trial, Orsiro demonstrated non-inferiority to Xience Prime for the primary endpoint at 12 months. A similar trend was shown throughout 24 months.
  • Orsiro, with its ultrathin struts and bioabsorbable polymer additionally presents superior results in the high-risk subgroup of patients presenting with ST-elevation myocardial infarction (STEMI) out to 24 months.

Patient and lesion characteristics1

Image
Patient Characteristics Table
Image
Lesion characteristics Table

Study Design

  • Prospective, all-comers, multicenter, randomized, non-inferiority design
  • Principal Investigator: Prof. Stephan Windecker, Bern, Switzerland
Image
Picture shows study design

Clinical results up to 24 months2

Image
Clinical results Graph

Stent thrombosis up to 24 months2

Image
Stent thrombosis Graph

STEMI subgroup up to 24 months3

Image
STEMI subgroup graph

Downloads


Image
Orsiro Image

Vascular Intervention

Drug-Eluting Stent

Image
Orsiro Image

Vascular Intervention

Clinical Study


Disclaimer
© BIOTRONIK AG – All rights reserved. Specifications are subject to modification, revision and improvement. excellence for life


1 Pilgrim T. et al., Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial, Lancet. 2014 Sept 1 (online).

Piccolo R. Biodegradable polymer Sirolimus-eluting stents vs. durable polymer Everolimus-eluting stents in patients with STEMI: Two-year follow-up of the BIOSCIENCE. EuroPCR 2016. Oral presentation.

2 Iglesias J., How the Orsiro DES performs in high-risk subgroups, oral presentation at EuroPCR 2015.

Definite and probable stent thrombosis according to ARC definition and adjudicated by independent clinical events committee.